



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico



THE MYELOMAS

2ND INTERNATIONAL MEETING

The present and the future in 2026:

Towards Tailored Therapy, Personalized Prognosis and
Precision Medicine Approaches for Enhanced Patient Care.

23 - 24 • **OCTOBER 2026**
THE HIVE HOTEL, ROME

PRESIDENTS:

Claudio Cerchione, Gerardo Musuraca, Antonino Musolino

HONORARY PRESIDENT:

Paul Richardson

SCIENTIFIC COMMITTEE:

Claudio Cerchione, Delia Cangini, Michela Ceccolini,
Sofia Cortesi, Matia Bernardi, Alessandro Lucchesi,
Giovanni Martinelli, Gerardo Musuraca, Sonia Ronconi

ORGANIZING SECRETARIAT



REGISTRATION



- ① Download the "PROEVENTI" app on your smartphone.
- ② Login or create a new account.
- ③ Enter the event pin: **MYELOMAS26**.
- ④ You are now on the event page, click on **"REGISTRATION"** at the top left.

The Conference has been accredited to the Italian Ministry of Health:

Event n. 491067 Provider 2773

ECM Credits n. 12 for:

100 Medical Surgeon (interdisciplinary area), Pharmacist.

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles – treatment profiles.

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

Participation at the event is free of charge, but registration is compulsory.
THE REGISTRATION DEADLINE IS 20 OCTOBER 2026.



PROMOTED BY



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

PATRONAGE



ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE
LINFOMI E MIELOMA



ASSOCIAZIONE
ITALIANA
ONCOLOGIA
MEDICA



eha



GITMO

GRUPPO ITALIANO TRAPIANTI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE



International
Myeloma Society



SIE – Società Italiana di Ematologia

FACULTY

ANDERSON KENNETH	HARVARD MEDICAL SCHOOL, BOSTON
BASSETTI MATTEO	UNIVERSITÀ DEGLI STUDI DI GENOVA, GENOVA
BEILHACK ANDREAS	UNIVERSITY OF WUERZBURG, WUERZBURG
BERNARDI MATIA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
BIANCO ROSARIO	A. O. R. N. SAN GIUSEPPE MOSCATI, AVELLINO (NA)
BRUNO BENEDETTO	UNIVERSITÀ DI TORINO, TORINO
CANGINI DELIA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
CARAVITA TOMMASO	ASL ROMA 1, ROMA
CAVO MICHELE	UNIVERSITÀ DI BOLOGNA, BOLOGNA
CECCOLINI MICHELA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
CELLINI CLAUDIA	OSPEDALE S. MARIA DELLE CROCI, RAVENNA
CERCHIONE CLAUDIO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
CORTESI SOFIA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
DA VIA' MATTEO CLAUDIO	UNIVERSITÀ DEGLI STUDI DI MILANO, MILANO
DE PAOLI LORENZO	OSPEDALE SANT'ANDREA, VERCELLI
DESANTIS VANESSA	UNIVERSITÀ DEGLI STUDI DI BARI, BARI
DIMOPOULOS MELETIOS A.	UNIVERSITY OF ATHENS, ATHENS
FAZIO FRANCESCA	AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO UMBERTO I , ROMA
FURLAN ANNA	OSPEDALE CA' FONCELLO, TREVISO
GARG MAMTA	LEICESTER ROYAL INFIRMARY, LEICESTER
LEE HANS CHARLES	SARAH CANNON RESEARCH INSTITUTE, NASHVILLE
LEE JI HYUN	DONG-A UNIVERSITY HOSPITAL, BUSAN
LELEU XAVIER	POITIERS UNIVERSITY HOSPITAL, POITIERS
LIBERATORE CARMINE	UNIVERSITÀ GABRIELE D'ANNUNZIO, CHIETI
LUCCHESI ALESSANDRO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)



LUDWIG HEINZ	WILHELMINEN CANCER RESEARCH INSTITUTE, VIENNA
MANGIACAVALLI SILVIA	FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO, PAVIA
MARCHESINI MATTEO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
MARTINELLI GIOVANNI	UNIVERSITÀ DI BOLOGNA, BOLOGNA
MATEOS MARIA VICTORIA	UNIVERSITY OF SALAMANCA, SALAMANCA
MOSQUERA ADRIAN	UNIVERSITY HOSPITAL OF SANTIAGO DE COMPOSTELA
MOREAU PHILIPPE	UNIVERSITY OF NANTES, NANTES
MUSOLINO ANTONINO	UNIVERSITÀ DI BOLOGNA, BOLOGNA
MUSURACA GERARDO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
MUSTO PELLEGRINO	UNIVERSITÀ DEGLI STUDI DI BARI, BARI
NAGLER ARNON	TEL AVIV UNIVERSITY, TEL AVIV
NERI PAOLA	UNIVERSITY OF CALGARY, CALGARY
NUNZIATA GIUSEPPE RODOLFO	OSPEDALE SAN G. MOSCATI, AVERSA
PAIVA BRUNO	UNIVERSITY OF NAVARRA, NAVARRA
POPAT RAKESH	UNIVERSITY COLLEGE HOSPITAL, LONDON
PROCHOWSKI IAMURRI A.	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
RICHARDSON PAUL	DANA FARBER CANCER INTITUTE/HARVARD
GERARD GUY	MEDICAL SCHOOL, BOSTON
ROMANO ALESSANDRA	UNIVERSITÀ DEGLI STUDI DI CATANIA, CATANIA
RONCONI SONIA	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
SCHJESVOLD FREDRIK	OSLO MYELOMA CENTER, OSLO
SIEGEL ARIEL	DANA FARBER CANCER INSTITUTE, BOSTON
SOLIMANDO ANTONIO	UNIVERSITÀ DI BARI ALDO MORO, BARI
SONNEVELD PIETER	ERASMUS UNIVERSITY MEDICAL CENTER, ROTTERDAM
SVANERA GINO	OSPEDALE SAN GIULIANO, GIUGLIANO (NA)
ZAMAGNI ELENA	UNIVERSITÀ DI BOLOGNA, BOLOGNA

GENERAL INFORMATION

WELCOME TO ROME & GENERAL INFO

LANGUAGE

The official language of the Congress is English. All presentations and scientific materials will be provided in English.

CLIMATE

The local climate in Rome during the event period is typically temperate. The average temperature ranges between 16°C and 27°C.

CURRENCY & BANKING

The official currency is the Euro (€). Foreign currencies can be exchanged at banks, which are generally open Monday to Friday, from 08:30 to 13:30. Most shops and restaurants accept major credit cards.

TAXI SERVICE

To call a taxi, the single number is 060609.

- From Fiumicino Airport: €48.
- From Ciampino Airport: €30.
- From Termini to city centre: between €8 and €15.

KEY INFORMATION

VENUE & GETTING AROUND

VENUE

The Hive Hotel – Rome, Italy.
Via Torino, n°6.



WIFI available in every area.

HOTEL INFORMATION

For hotel information and reservation please visit the Hotel & Groups Desk.

The hotel is just a 5-minute walk from Roma Termini Station.

Exit the station through the main entrance onto **Piazza dei Cinquecento**.

Turn left and cross the road at the traffic lights.

Continue along **Via Massimo D'Azeglio** for approximately 250 metres,
then turn right onto **Via Torino**.

The hotel is about 20 metres ahead on your right.

We wish you a pleasant stay!


SCIENTIFIC RATIONALE



In the last decades, survival rates of Multiple Myeloma have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation. Moreover, in the last few years, the MM therapeutic “toolbox” has improved further with the approval in new generation IMiD (pomalidomide), the monoclonal antibodies, daratumumab and elotuzumab, as well as the new-generation proteasome inhibitors,

carfilzomib and ixazomib, waiting for introduction in daily practice of novel agents with new mechanism of action (Belantamab, CAR-T). At the same time, there is increasing understanding of MM tumor biology, creating the rationale for new combinations of drugs and new therapy development. Discovery of the associated cytogenetic abnormalities confirm the hypothesis that MM is a heterogeneous disease, suggesting that riskadapted therapies and individualizing treatment will further help improve patient management. The aim of this event is the discussion between international and national experts.

23 OCTOBER
2026



DAY 1

8:15 REGISTRATION

8:30/9:00 WELCOME AND INTRODUCTION

Claudio Cerchione - Gerardo Musuraca

09:00 - 09:20

Chairs: C. Cerchione, G. Musuraca

- **B. Paiva**

Opening Brian Durie Lecture: The Importance of MRD in Multiple Myeloma

09:20 - 09:40

- **M. Bassetti**

Plenary Lecture: Vaccinations and infectious prophylaxis after new drugs

→ **SESSION 1:**

New insights into the Biology of Plasma Cell Dyscrasias

Chairs: B. Paiva, E. P. Neri, R. Bianco, T. Caravita

09:40 - 10:00

- **M. Da Vià**

How to integrate MRD in our daily practice

10:00 - 10:20

- **A. Romano**

From research to the clinical practice: the milestones of Myeloma biology

10:20 - 10:40

- **E. P. Neri**

Anti-BCMA Drugs - Overcoming resistance

10:40 - 11:00

- **A. Mosquera**

New insights into the Biology of Plasma Cell Dyscrasias

DAY 1

11:00 - 11:30

New models (“Gene and Imagine”) for integrated multidisciplinary approach to detect new generation risk adapted index in Multiple Myeloma (and SMM) – The GIMPI Project

- **M. Marchesini**

Biology perspective

- **A. Prochowski lamurri and C. Cerchione**

Radiology perspective

11:30 - 11:50

- Discussion: Faculty Chairs and Speakers

11:50 - 12:10 COFFEE BREAK

→ **SESSION 2:**

Multiple Myeloma - State of the art

Chairs: M.V. Mateos - P. Musto - A. Siegel

12:10 - 12:30

- **M. V. Mateos**

How I manage Smoldering Myeloma: Risk Stratification and Management

12:30 - 12:50

- **A. Siegel**

Is it time for biomarkers-driven approach in Smoldering Myeloma?

12:50 - 13:00

- Discussion: Faculty Chairs and Speakers

DAY 1

13:00 - 13:40 LUNCH SYMPOSIUM
ROOM: CRYSTALSponsored Symposium NO ECM -
with the contribution of Johnson & Johnson

Beyond Today's Peak: Shaping the Future of Multiple Myeloma

13:00

• **C. Cerchione**

Welcome and Introduction

13:10

• **S. Mangiacavalli**

Reaching New Frontiers in Newly Diagnosed Multiple Myeloma

13:20

• **M. C. Da Vià**

Exploring New Horizons for Triple-Class Exposed Multiple Myeloma Patients

13:30

• **C. Cerchione, S. Mangiacavalli, M. C. Da Vià**

Key Takeaways

Special Guest: **Licia Colò** - Conduttrice e divulgatrice di ambiente, salute e benessere.→ **SESSION 3:****Frontline setting: where are we going?****Chairs: C. Cerchione, M. Cavo, P. Sonneveld, X. Leleu**

13:50 - 14:10

• **C. Cerchione**

Multiple Myeloma – Perspectives from Europe

14:10 - 14:30

• **P. Sonneveld**

Transplant-eligible patients – today and tomorrow

DAY 1

14:30 - 14:50

- *X. Leleu*

Transplant-ineligible patients – today and tomorrow

14:50 - 15:10

- *A. Furlan*

Is there a role for consolidation in the era of novel agents?

15:10 - 15:30

- *M. Garg*

Role of maintenance and with which drug, in the new era of Myeloma

15:30 - 15:50 COFFEE BREAK

→ **SESSION 4:**

Moving beyond Multiple Myeloma and Barriers to Cure:

Chairs: C. Cellini, D. Cangini, A. Nagler, F. Schjesvold

15:50 - 16:30

From ADCs to Bispecific antibodies and CAR-T. How to integrate in the best sequencing: What we can and what we would do?

- *F. Schjesvold*

In earlier lines

- *T. Dimopoulos*

Later lines and new compounds

16:30 - 16:50

Chairs: C. Cerchione, G. Musuraca, G. Martinelli

- *K. Anderson*

Plenary Lecture 1: Multiple myeloma – Translational and Clinical milestones in the History of Treatment over the last 30 years

DAY 1

16:50 - 17:30

Debate: Should we continue to transplant myeloma?

- *A. Nagler*

Yes

- *E. Zamagni*

No

17:30 - 17:40

- Discussion: Faculty Chairs and Speakers

17:40 CLOSING DAY REMARKS

Claudio Cerchione - Gerardo Musuraca

24 OCTOBER
2026



DAY 2

8:30 WELCOME TO DAY 2
Claudio Cerchione - Gerardo Musuraca

08:30 - 08:50

Chairs: C. Cerchione, G. Musuraca

• **P. G. Richardson**

Plenary Lecture 2: Multiple Myeloma – A Revolutionary Road and the evolving Strategic Paradigm of Therapy: What's Next?

→ SESSION 5:

From Guidelines to Clinical Practice - EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up in Multiple Myeloma: what is changing?

Chairs: C. Cerchione, H. Ludwig, P. Moreau, A. Solimando

08:50 - 09:10

• **P. Moreau**

Frontline setting

09:10 - 09:30

• **C. Liberatore**

Relapsed/refractory setting – Early relapses

09:30 - 09:50

• **H. Ludwig**

Relapsed/refractory setting – Later relapses

09:50 - 10:20

High Risk and Ultra High-Risk Myeloma:

• **V. Desantis**

How to define

• **A. Solimando**

How to treat?

10:20 - 10:40

• Discussion: Faculty Chairs and Speakers

10:40 - 11:00 COFFEE BREAK

DAY 2

→ SESSION 6:

The New Era of Immunotherapy; Opportunities and Challenges

Chairs: R. Popat, L. De Paoli, S. Mangiacavalli, G. Svanera

11:00 - 11:20

• **H. Lee**

Diagnosis and management of MM -related AL Amyloidosis

11:20 - 11:40

• **R. Popat**

Diagnosis and management of Plasma Cell Leukemia

11:40 - 12:00

• **J. H. Lee**

Extramedullary Disease – Pathobiology and Treatment

12:00 - 12:20

• **B. Bruno**

Plenary Lecture: Redefining Cellular Therapy in Multiple Myeloma: Beyond Today's CAR-T Cells

12:20 - 12:40

• Discussion: Faculty Chairs and Speakers

→ SESSION 7:

New Drugs in Multiple Myeloma:

Chairs: C. Liberatore, A. Lucchesi, G. Nunziata, F. Fazio

12:40 - 13:00

• **H. Ludwig**

Peptide drug conjugates

13:00 - 13:20

• **P. G. Richardson**

CELMoDs, targeting XPO1, and inhibiting p300 and Bcl-2 In MM

DAY 2

13:20 - 13:40

- **A. Beilhack**

Other New and Emerging targets

13:40 - 14:00

- **P. G. Richardson**

New insights into relapsed, refractory multiple myeloma and immune exhaustion

14:00 - 14:10

- Discussion: Faculty Chairs and Speakers

14:10 CLOSING DAY REMARKS

Claudio Cerchione - Gerardo Musuraca

SEE YOU NEXT YEAR!

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

GOLD

Johnson & Johnson

SILVER



BRONZE



Shaping the next era of Multiple Myeloma care.

International experts discussing the latest advances in biology, targeted therapies, immunotherapy and personalized treatment strategies.